Peritoneal carcinomatosis (PC) is a devastating form of cancer progression with a very poor prognosis. Chemotherapy has only limited effect due to drug resistance in advanced tumor stages and to poor bioavailability within the abdominal cavity after systemic drug application. Current therapy, when possible, includes cytoreductive surgery associated or not with hyperthermic intraperitoneal chemotherapy \[[@CR1]\]. However, this therapy is linked to significant morbidity and mortality, and results are still limited \[[@CR2]\]. Thus, there is a need for novel therapeutic approaches, including preventive strategies during initial surgery \[[@CR3]\].

The ability of cancer cells to recognize damage and initiate DNA repair is an important mechanism of resistance to treatment. Pharmacological inhibition of DNA repair for a short period during treatment has the potential to make cancer cells more vulnerable to the damaging effects of therapy, therefore increasing the response to treatment \[[@CR4]\]. Dbait acts by baiting and hijacking the enzyme complexes that repair DNA double strand breaks (DSB), diverting them away from their primary objective, the DSBs on chromosomes \[[@CR5]\]. Such DSB are currently caused by treatment, such as radiotherapy (RT) and DNA-damaging chemotherapy (CT). Dbait increases the sensitivity of HNCC, melanoma and glioblastoma to irradiation \[[@CR6]\], and the sensitivity of colorectal cancer to chemotherapy \[[@CR7]\]. However, a limitation of this approach is tumor access and penetration into tumor nodes, so that it can only be applied to superficially spreading tumors.

Laparoscopy offers a unique opportunity to control and to steer the operating environment during surgery, by loading carbon dioxide with a therapeutic substance and creating the so-called therapeutic capnoperitoneum \[[@CR8]\]. Recently, we have shown that therapeutic peritoneum allows homogeneous distribution of a therapeutic substance within the peritoneal cavity and an improved penetration depth into normal and diseased tissue compared with conventional peritoneal lavage \[[@CR9]\].

However, working with toxic therapeutic aerosols is only possible under strongly regulated conditions. Interestingly, preclinical studies with Dbait in the primate have shown no toxicity of the molecule on healthy tissues (data on file). Thus, there is a rationale for combining Dbait with therapeutic capnoperitoneum to obtain a synergy. In particular, local increase in chemosensitivity could improve efficacy of both intraperitoneal and systemic chemotherapy on PC.

The general purpose of the present ex vivo experiment was to test possible advantages of combining both technologies for treating a human PC tumor nodule, in particular concerning tumor access (distribution and penetration). A second specific goal was to examine whether genotoxicity can be demonstrated in a tumor nodule of human PC after loading capnoperitoneum with Dbait.

Material and methods {#Sec1}
====================

The current study was designed to investigate the biodistribution of Dbait in a PC nodule ex vivo, immediately after surgical resection. For this purpose, a tumor nodule was exposed to Dbait aerosol using the micropump (MIP) spraying device under 12 mmHg of CO~2~ pressure in a closed box modeling the peritoneal cavity. An electrical gradient was generated to focus drug distribution onto the peritoneal surface and to enhance tissue penetration (Fig. [1](#Fig1){ref-type="fig"}). As controls, two further experiments were conducted: (1) the experiment as above without Dbait, and (2) lavage of a PC nodule with Dbait in a glucose solution.Fig. 1Laparoscopy-like ex vivo experiment on fresh operation specimen of diseased human peritoneum (peritoneal carcinomatosis from endometrial origin). Therapeutic capnoperitoneum (12 mmHg) was established in a plastic box. An electrostatic gradient of 60 V was generated between the MIP and the biological tissue, placed on a neutral electrode. *MIP* micropump

The following parameters have been measured:Surface homogeneity of Dbait distribution within the simulated peritoneal cavity,Dbait diffusion into the peritoneal nodule, andDbait's bioactivity in cancer cells under oxidative stress.

Study design {#Sec2}
------------

This ex vivo study involved tumor tissue from a single human patient suffering PC from endometrial origin. Because patient therapy was not influenced by the experiment, no authorization from an ethical committee was required. Ex vivo research on human tissue is allowed at our institution by a valid authorization of the common ethics committee of the Westfalian University---Medical Chamber of Westfalia-Lippe (AeKWL).

Nebulizer {#Sec3}
---------

The nebulizer has been described elsewhere \[[@CR9]\] and consists of several components, including an injector, a line, and a nozzle. The nozzle had a diameter of 0.2 mm, and a pressure of approximately 8 bars was delivered upfront of the nozzle. The nebulizer was inserted through a 10-mm trocar and generated an aerosol within the plastic box mimicking the abdominal cavity. The gaseous phase consisted of CO~2~, the liquid phase of microparticles of Dbait (100 μg/ml).

Patient characteristics, cytoreduction, and intraperitoneal hyperthermic chemotherapy {#Sec4}
-------------------------------------------------------------------------------------

A female patient suffering PC from endometrial cancer was selected for the experiment and gave her written, informed consent. Chloroquine 100 mg qd was administered for 1 week before the operation. First, a complete cytoreduction was achieved (CRS). In a second step, intraperitoneal hyperthermic chemotherapy was applied with cisplatin 75 mg/m^2^ body surface and doxorubicin 15 mg/m^2^ body surface, according to usual protocols.

Tumor characteristics {#Sec5}
---------------------

Immediately after surgical cytoreduction, a peritoneal fragment of approximately 10 × 10 cm, showing macroscopic peritoneal nodules, was selected for experimental purpose. The remaining surgical specimen was sent to the pathologist for diagnostic purpose. Microscopic analysis showed a poorly differentiated (G3) clear cell adenocarcinoma with few small necrosis foci.

Experimental protocol {#Sec6}
---------------------

The three surgical samples were treated as follows:The first peritoneal nodule was inserted into the experimental box, placed on the electrode, and exposed to CO~2~ capnoperitoneum at room temperature for 30 minutes. After dilution into 90 ml of glucose 5%, 9 mg of Cy5-labelled Dbait (1:1 dilution with non fluorescent Dbait) was aerosolized into the box.A second peritoneal nodule was exposed to "peritoneal lavage" using 0.1 mg/ml Dbait-Cy5 diluted into 10 ml of glucose 5%.A third peritoneal nodule was exposed to identical conditions as (a) without Dbait (negative control).

Immediately after the experiment, all three samples were split into two halves: the first half was fixed in formalin solution and sent to the pathologist, the second half was immediately frozen at −80°C for further biological analysis.

Microscopic analysis {#Sec7}
--------------------

For analysis, formalin-fixed specimens were stained with H&E according to usual protocols. For microscopic fluorescence analysis, sampled were fixed with PFA 4% for 20 min at room temperature (RT), followed by exposure to Triton 0.5% for 10 min at RT. Then, samples were washed out in SVF diluted ½ in PBS solution for 1 h at RT, followed by incubation with γ-H2AX mouse antibody (Millipore, Billerica, MA, USA) diluted 1/200 (SVF ½ in PBS) for 2 h at RT. After washing, samples were incubated with secondary anti-mouse FITC (Sigma-Aldrich Chimie Sarl., Lyon, France) diluted 1/100 for 45 min at RT. Nuclei were counterstained with Dapi 0.5 μg/ml for 5 min at room temperature. Analysis was performed with an inverted microscope.

Results {#Sec8}
=======

The experiment was performed according to the schedule. No technical difficulty was encountered. In particular, MIP generated the Dbait-aerosol without any difficulty. Remote control of the injection device was possible without direct intervention in the operating room. All six sides of the experimental box were stained; however, an intensity gradient was observed from the bottom to the top of the box (not shown).

Microscopic analysis revealed homogeneous peritoneal distribution of Dbait-Cy5 in the therapeutic capnoperitoneum sample (arrows), only minimal uptake in the lavage sample, and no staining (or only marginal staining) in the control sample (Fig. [2](#Fig2){ref-type="fig"}). Fluorescence was detected within the tumor up to 1 mm depth in the therapeutic capnoperitoneum sample but not in the lavage sample (Fig. [3](#Fig3){ref-type="fig"}). Thus, aerosolization of the molecule allowed significantly better tumor access and better bioavailability of Dbait than conventional lavage.Fig. 2Diffusion of therapeutic substance onto the peritoneum. I. Cryosection of human peritoneum, *red*: Dbait-Cy5 staining, *blue*: Dapi (nucleus). **A** After nebulization of Dbait, **B** after lavage with Dbait, **C** after nebulization without Dbait. Staining reveals homogeneous peritoneal fluorescence in the therapeutic capnoperitoneum sample (*arrows*), only minimal uptake in the lavage sample, and no staining in the control sample. II: H&E stainingFig. 3Penetration of therapeutic substance into the peritoneum. Cryosection of human peritoneum, *red*: Dbait-Cy5 staining, *blue* dapi (nucleus). **A** After nebulization of Dbait, **B** after lavage with Dbait, **C** after nebulization without Dbait. Staining reveals fluorescence up to seven cellular layers in the therapeutic capnoperitoneum sample (**A**), no tissue uptake in the lavage sample (**B**) and no staining in the control sample (**C**)

Biological results showed intranuclear phosphorylation of H2AX in the nebulized sample and almost no activity in the lavage sample (Fig. [4](#Fig4){ref-type="fig"}). The low activity detected in the lavage sample is due to the presence of spontaneous chromosomal damage in PC cells. Detection of histone gamma-H2AX (phosphorylated H2AX) reveals the nuclear activation of DNA-dependent protein kinase (DNA-PK) by Dbait. Dbait was taken up by cancer cells, and a biological activity was detected up to 1 mm depth. Importantly, tumor nodules showed more activity at the tumor invasion front (Fig. [5](#Fig5){ref-type="fig"}).Fig. 4Biological activity. Cryosection of human peritoneum. Detection of early Dbait activity marker: Phosphorylated H2AX. *Red*: Dbait-Cy5 staining, *blue*: Dapi staining (nucleus), *green*: γ-H2AX. **A** After nebulization of Dbait, **B** after lavage with Dbait. Intranuclear phosphorylation of H2AX is observed the nebulized sample and only artifactual staining (no nuclear staining) in the lavage sample. Detection of histone γ-H2AX (phosphorylated H2AX) reveals activation of DNA-Phosphokinase by Dbait, which has been shown to be the key step for sensibilization to genotoxic therapyFig. 5Tumor specificity. Detection of early Dbait activity marker: cryosection of human peritoneum; **A***blue*: Dapi staining (nucleus); **B***green*: γ-H2AX after nebulization of Dbait, **C***red*: Dbait-Cy5 staining, **D** merged: H2AX activation is maximal at the tumor invasion front (*arrow*)

Discussion {#Sec9}
==========

This ex vivo experiment was designed to examine possible advantages of combining Dbait with therapeutic capnoperitoneum for treating a human tumor nodule of PC ex vivo, in particular concerning tumor access (distribution and penetration). A second specific goal was to examine whether bioactivity of Dbait could be demonstrated.

This is the first time that biological activity of Dbait is proved in human patient tissue. So far, experiments have been performed in human tumor xenograft models in the animal. This is significant progress toward regulatory approval of Dbait for therapeutic use in patients.

The above-mentioned results are encouraging, because they evidence a homogeneous distribution of Dbait onto peritoneum and a better penetration into peritoneum than after conventional peritoneal lavage. This excellent bioavailability of Dbait in human peritoneal tissue ex vivo confirms the results obtained previously in the large-animal model showing a better vital staining of the abdominal cavity after aerosolization than after lavage with methylene blue \[[@CR9]\].

Another important finding was intranuclear phosphorylation of H2AX in the nebulized sample, proving Dbait uptake up to 1 mm depth, and showing biological activity. Detection of histone gamma-H2AX (phosphorylated H2AX) reveals nuclear activation of DNA-PK by Dbait, a significant result because this activation has been shown to be the key step for sensibilization to genotoxic therapy \[[@CR5], [@CR6]\]. Moreover, this result has been obtained under oxidative stress conditions (warm ischemia) in human tumoral tissue---and not in an animal model. Importantly, tumor nodules showed more activity than the neighbor, normal peritoneum, in particular at the tumor invasion front. Thus, the present experiment delivers the proof of principle for combining Dbait with systemic or intraperitoneal chemotherapy to produce significant synergy. Of course, this proof of principle ex vivo should now be confirmed by corresponding in vivo studies.

Current intraperitoneal hyperthermic chemotherapy guidelines recommend the application of an intraperitoneal temperature of 41--43°C \[[@CR10]\]. Recently, we observed that numerous Heat Shock proteins were phosphorylated in cells treated by Dbait. Moreover, in vitro, Dbait sensitize cells to temperature shift (unpublished data). Thus, it will be interesting to perform these efficacy studies under hyperthermic conditions to increase the biological effect of Dbait.

In this experiment, biological response was observed already after less than 1 h. This was a surprise because preclinical data obtained in the animal model showed maximal biological response after 3 h. This can be explained by the application of an electrostatic gradient of 60 V, which is similar to the condition of cellular electroporation. This was obviously helpful for uptake of very large amounts of Dbait molecules. Preoperative therapy with chloroquine also might have contributed to this improved cellular drug uptake: chloroquine is known to fragilize the membranes of the endosomes, so that the release of Dbait molecules into the cytoplasm is facilitated \[[@CR11]\].

The biological effect was achieved with a low Dbait dose, only 9 mg for a volume corresponding to the entire abdominal cavity. Dbait effect is strictly dose-dependent, as demonstrated in several tumor systems \[[@CR6]\]. In the preclinical model, a dose of 4 mg was considered adequate for treating small tumor xenografts (data submitted). Thus, an excellent intracellular uptake of Dbait was achieved under experimental conditions.

Another, major point of interest is that Dbait has shown no toxicity in preclinical studies in the primate (data on file). Thus, aerosolization of Dbait might be possible in clinical practice without particular safety measures for protecting both patient and surgical team. This favorable safety profile might speed up implementation of therapeutic capnoperitoneum in cancer surgery.

In summary, combining Dbait with therapeutic capnoperitoneum appears to have several practical advantages. Peritoneal carcinomatosis is a superficial and diffuse tumor that is accessible to Dbait. Pressure enhances Dbait penetration into tumor tissue. CO~2~ as a carrier ensures excellent drug distribution onto the peritoneum. Application of an electrostatic gradient optimizes both drug distribution and drug uptake, probably by inducing cellular electroporation. Dbait has no toxicity demonstrated in the primate so that its clinical use appears easily possible. Finally, intraperitoneal hyperthermia might enhance the efficacy of Dbait by creating cellular stress, but this has not been investigated in the present proof-of-principle experiment.

The development of procedures easily applicable to the clinical setting that might improve outcome in PC should be given high priority. This proof-of-principle experiment opens a new avenue for treating PC that should now be followed by adequate clinical studies, a precondition for regulatory approval of this new, challenging therapeutic approach.
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